Anavex

What Anavex does

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing oral small-molecule therapeutics for central nervous system (CNS) disorders, including Alzheimer's disease, Parkinson's disease dementia, Rett syndrome, and schizophrenia. The company's pipeline is built on the proprietary SIGMACEPTOR Discovery Platform, which identifies therapeutic candidates that activate the SIGMAR1 receptor to enhance autophagy and restore cellular homeostasis in neurons. Its lead candidate, blarcamesine (ANAVEX2-73), is an orally administered SIGMAR1 activator that has completed Phase IIb/III trials in early Alzheimer's disease and Phase II/III trials in Rett syndrome; it holds FDA Orphan Drug and Rare Pediatric Disease Designations for Rett syndrome. The company applies a precision-medicine strategy called ABCLEAR, stratifying patients by genetic markers (wild-type SIGMAR1, approximately 70% of the global population) to identify likely responders. Additional pipeline assets include ANAVEX3-71, a dual SIGMAR1/M1 muscarinic receptor agonist in Phase 2 for schizophrenia, and preclinical candidates ANAVEX1-41 and ANAVEX1066.

Anavex has no commercialized products and therefore no product revenue. The business model is that of a pre-commercial biotech: capital is raised in equity markets to fund R&D and clinical development, with future revenue contingent on regulatory approval and commercialization of drug candidates through standard pharmaceutical distribution channels. Following a negative CHMP opinion in November 2025 and subsequent withdrawal of its EU marketing authorization application for blarcamesine in March 2026, the company has shifted its regulatory focus toward an FDA NDA pathway in early Alzheimer's disease, supported by a January 2026 Type C meeting. The company is publicly listed on NASDAQ (ticker: AVXL), headquartered in New York, NY, and operates with 11-50 employees.

As of December 31, 2025, Anavex held $131.7 million in cash and cash equivalents with no long-term debt, providing more than three years of estimated runway, augmented by a US$150 million equity offering completed in August 2025. The company has experienced significant turbulence in 2026, including the departure of CEO Christopher Missling, the appointment of Terrie Kellmeyer as Interim CEO, multiple securities-fraud investigations, a Nasdaq delinquency notification for delayed 10-Q filing, and a stock decline of approximately 56% over the prior six months. Q1 2026 net loss was reduced to $5.7M from $12.1M year-over-year, reflecting lower operating costs.

Name

Anavex

Legal name

Anavex Life Sciences Corp.

Website

https://anavex.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Anavex Life Sciences is a clinical-stage biopharmaceutical company developing oral small-molecule SIGMAR1-activator therapies, with lead candidate blarcamesine for Alzheimer's disease, Parkinson's disease dementia, and Rett syndrome. It applies genetic precision-medicine stratification, has no approved products, and focuses on CNS drug development.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

Keywords

• Clinical-stage biopharmaceuticals
• Neurodegenerative disease therapeutics
• SIGMAR1 receptor activation
• Alzheimer's disease drug development
• Precision medicine CNS

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Revenue: Anavex is a clinical-stage biopharmaceutical company with no commercialized products. Revenue will be generated from sales of approved drug candidates including blarcamesine for Alzheimer's disease, Parkinson's disease, and Rett syndrome upon successful regulatory approval.
2. Drug Development Pipeline: The company is advancing multiple clinical programs: blarcamesine (Phase IIb/III for Alzheimer's, Phase II/III for Rett syndrome, Phase II for Parkinson's disease dementia), ANAVEX3-71 (Phase 2 for schizophrenia), and ANAVEX1-41 (preclinical).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Anavex Life Sciences is a clinical-stage biopharmaceutical company developing oral small-molecule drug candidates that activate the SIGMAR1 receptor to restore autophagy in neurons. Its lead candidate, Blarcamesine (ANAVEX2-73), targets Alzheimer's disease, Parkinson's disease dementia, and Rett syndrome, with additional pipeline assets including ANAVEX3-71 for schizophrenia. The company has no commercialized products and generates no product revenue, with drugs still in clinical or regulatory stages.

Product overview

Anavex Life Sciences is a clinical-stage biopharmaceutical company developing a portfolio of investigational oral therapies for central nervous system (CNS) disorders. The company's lead product is Blarcamesine (ANAVEX®2-73), an oral SIGMAR1 activator that enhances autophagy and has completed Phase IIb/III trials for Alzheimer's disease and Phase II/III trials for Rett syndrome. The second pipeline product is ANAVEX®3-71, a dual SIGMAR1 and M1 muscarinic receptor agonist in Phase 2 development for schizophrenia. Additional compounds include preclinical-stage ANAVEX®1-41 and ANAVEX®1066. The company's proprietary SIGMACEPTOR Discovery Platform underpins its therapeutic approach, and it employs an ABCLEAR precision medicine approach for patient stratification. Anavex is not a software/API product company; it focuses exclusively on small-molecule drug development.

Differentiator

Problem solved

Functional benefit

Brands

• SIGMACEPTOR: Anavex's proprietary discovery platform focusing on developing therapeutic candidates that activate SIGMAR1, such as Blarcamesine (ANAVEX2-73).

Products and services

• Blarcamesine (ANAVEX2-73) Investigational oral small-molecule therapy that enhances autophagy through SIGMAR1 activation. Being studied for Alzheimer's disease, Parkinson's disease dementia, and Rett syndrome. Has completed Phase IIb/III trials for early Alzheimer's disease and Phase II/III trials for Rett syndrome.
• ANAVEX3-71 Clinical-stage dual SIGMAR1 and M1 muscarinic receptor agonist being developed as an investigational therapy for schizophrenia. Demonstrated disease-modifying activity against Alzheimer's hallmarks in preclinical models.
• ANAVEX1-41 Preclinical-stage compound in Anavex's pipeline being developed for central nervous system disorders.
• ANAVEX1066

Quantifiable outcome

• 78% improvement in correlation strength for ADAS-Cog13 in genetically defined ABCLEAR population
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• ACCESS-AD Program (European Commission)coreStrategic or Co-development Partner · 13 January 2026Anavex joined ACCESS-AD, a major initiative funded by the European Commission, through the clinical evaluation of blarcamesine as part of a precision medicine approach in Alzheimer's disease. This European Commission-funded program supports the company's regulatory and clinical development strategy.
• ERP Biomarker Qualification ConsortiumminorStrategic or Co-development PartnerCollaboration with industry-led consortium for EEG/ERP biomarker qualification in schizophrenia clinical trials, leveraging validated automated data analysis pipeline and normative EEG/ERP data in patients with schizophrenia.
• U.S. Food and Drug Administration (FDA)coreOthersOngoing regulatory engagement with FDA including Type C meeting in January 2026 to discuss potential pathways toward New Drug Application for blarcamesine in early Alzheimer's disease. FDA reviewed blarcamesine's scientific profile noting absence of significant safety concerns and lack of ARIA across trials.
• European Medicines Agency (EMA)coreOthersEngagement with EMA's Committee for Medicinal Products for Human Use (CHMP) for blarcamesine marketing authorization application in EU. Following negative CHMP opinion in December 2025, Anavex withdrew application in March 2026 and continues dialogue with EMA. Also pursuing regulatory engagement for Parkinson's disease and Rett syndrome.
• University of California ResearchersminorStrategic or Co-development PartnerCollaborative peer-reviewed research published in PNAS Nexus proposing autophagy failure as precursor to amyloid beta and tau pathology, supporting scientific rationale for blarcamesine's mechanism of action targeting SIGMAR1 activation.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• vTv Therapeutics: Clinical-stage small-molecule developer focused on CNS and metabolic diseases, including Alzheimer's programs. Comparable as a small-molecule CNS pipeline peer at similar development stage.
• Cortexyme (Lighthouse Pharma): Clinical-stage biopharma focused on Alzheimer's disease therapeutics. Comparable as an emerging clinical-stage peer in the Alzheimer's indication with novel-mechanism pipeline.
• Karuna Therapeutics (acquired by Bristol Myers Squibb): Developed xanomeline-trospium for schizophrenia prior to BMS acquisition. Direct mechanism/indication peer to Anavex's ANAVEX3-71 schizophrenia program given muscarinic-receptor overlap.

Direct peers

• Sage Therapeutics: CNS-focused biopharma developing neuropsychiatric and neurology therapies (e.g., Zurzuvae for postpartum depression). Comparable as a small-cap CNS clinical/commercial peer with similar therapeutic categories.
• Acadia Pharmaceuticals: CNS-focused specialty pharmaceutical company with commercial CNS products (e.g., Nuplazid for Parkinson's psychosis, Daybue for Rett syndrome). Direct peer given overlapping CNS/Rett focus and specialty pharma positioning.
• Axsome Therapeutics: Commercial-stage CNS specialty pharma with FDA-approved products for depression and migraine. Comparable as a small-cap CNS company that has successfully navigated from clinical development to commercialization in neuropsychiatry.
• BioXcel Therapeutics: Clinical-stage biopharma developing neuroscience and immuno-oncology therapies, with approved product IGALMI for agitation in schizophrenia/bipolar. Direct peer as another small-cap CNS commercializing company.
• Cassava Sciences: Clinical-stage biopharma focused on oral small-molecule therapy (simufilam) for Alzheimer's disease. Closest peer to Anavex by indication, stage, and oral-mechanism thesis in CNS.

Broad incumbents

• Biogen: Large commercial-stage neuroscience biopharma and co-developer of Leqembi for Alzheimer's disease. Relevant as the established commercial competitor in early Alzheimer's with full commercialization infrastructure.
• Eli Lilly: Global pharmaceutical incumbent with Kisunla approved for early Alzheimer's disease. Sets the competitive benchmark for any Alzheimer's commercialization and is the dominant incumbent competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/anavex_news
• Facebookfacebook.com/752348178140245
• LinkedInlinkedin.com/company/anavex-life-sciences
• Instagraminstagram.com/anavexlifesci

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anavex